Erythropoietin in the prevention of experimental burn progression

Tobalem, Mickaël; Harder, Yves; Schuster, Tilmann; Rezaeian, Farid; Wettstein, Reto

doi:10.1002/bjs.8847

Cited by 21 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is notable that previous experimental treatments of burn wounds using EPO itself have also shown tissue protection (32)(33)(34)(35) and invoked mechanisms other than anti-inflammatory. Therefore, apart from a predominant focus on innate immunity, our findings could also be considered as only one aspect of a net effect of ARA290 on different cell types within tissues/wounds.…”

Section: Discussionmentioning

confidence: 99%

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns

Bohr

Patel

Shen

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Alternate erythropoietin (EPO)–mediated signaling via the heteromeric receptor composed of the EPO receptor and the β-common receptor (CD131) exerts the tissue-protective actions of EPO in various types of injuries. Herein we investigated the effects of the EPO derivative helix beta surface peptide (synonym: ARA290), which specifically triggers alternate EPO-mediated signaling, but does not bind the erythropoietic EPO receptor homodimer, on the progression of secondary tissue damage following cutaneous burns. For this purpose, a deep partial thickness cutaneous burn injury was applied on the back of mice, followed by systemic administration of vehicle or ARA290 at 1, 12, and 24 h postburn. With vehicle-only treatment, wounds exhibited secondary microvascular thrombosis within 24 h postburn, and subsequent necrosis of the surrounding tissue, thus converting to a full-thickness injury within 48 h. On the other hand, when ARA290 was systemically administered, patency of the microvasculature was maintained. Furthermore, ARA290 mitigated the innate inflammatory response, most notably tumor necrosis factor-alpha–mediated signaling. These findings correlated with long-term recovery of initially injured yet viable tissue components. In conclusion, ARA290 may be a promising therapeutic approach to prevent the conversion of partial- to full-thickness burn injuries. In a clinical setting, the decrease in burn depth and area would likely reduce the necessity for extensive surgical debridement as well as secondary wound closure by means of skin grafting. This use of ARA290 is consistent with its tissue-protective properties previously reported in other models of injury, such as myocardial infarction and hemorrhagic shock.

show abstract

Section: Discussionmentioning

confidence: 99%

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns

Bohr

Patel

Shen

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…In a previous study using the rat comb burn model, application of EPO 500 at 6 hours after burn induction did not result in prevention of burn progression as did early administration after 45 minutes, indicating that rapid action is necessary to prevent burn progression (29). Also, the interval that permits salvage of this zone of stasis is probably variable.…”

Section: Discussionmentioning

confidence: 91%

Secondary Burn Progression Decreased by Erythropoietin*

Tobalem

Harder

Rezaeian

et al. 2013

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…In our review, several studies over the last five years examined the role of erythropoietin (EPO), a hormone with known anti-inflammatory, angiogenic, and vasodilatory properties [74–76], in the prevention and treatment of burn wound progression [75]. Tobalem et al demonstrate that treatment with EPO limits interspace necrosis and burn depth extension in a dose-dependent manner in a comb burn model [76].…”

Section: Discussionmentioning

confidence: 99%

“…Tobalem et al demonstrate that treatment with EPO limits interspace necrosis and burn depth extension in a dose-dependent manner in a comb burn model [76]. Interestingly, while both high and low-dose EPO upregulated inducible nitric oxide synthase (iNOS) and decreased inflammation, only low-dose EPO treatment prevented burn progression.…”

Section: Discussionmentioning

confidence: 99%

Current concepts on burn wound conversion—A review of recent advances in understanding the secondary progressions of burns

Salibian

Rosario

Severo

et al. 2016

Burns

View full text Add to dashboard Cite

Burn wound conversion describes the process by which superficial partial thickness burns convert into deeper burns necessitating surgical intervention. Fully understanding and thus controlling this phenomenon continues to defy burn surgeons. However, potentially guiding burn wound progression so as to obviate the need for surgery while still bringing about healing with limited scarring is the major unmet challenge. Comprehending the pathophysiologic background contributing to deeper progression of these burns is an essential prerequisite to planning any intervention. In this study, a review of articles examining burn wound progression over the last five years was conducted to analyze trends in recent burn progression research, determine changes in understanding of the pathogenesis of burn conversion, and subsequently examine the direction for future research in developing therapies. The majority of recent research focuses on applying therapies from other disease processes to common underlying pathogenic mechanisms in burn conversion. While ischemia, inflammation, and free oxygen radicals continue to demonstrate a critical role in secondary necrosis, novel mechanisms such as autophagy have also been shown to contribute affect significantly burn progression significantly. Further research will have to determine whether multiple mechanisms should be targeted when developing clinical therapies.

show abstract

Erythropoietin in the prevention of experimental burn progression

Cited by 21 publications

References 25 publications

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns

Secondary Burn Progression Decreased by Erythropoietin*

Current concepts on burn wound conversion—A review of recent advances in understanding the secondary progressions of burns

Contact Info

Product

Resources

About